UnitedHealth Backlash Signals Possible Shift in Washington and on Wall Street

UnitedHealth Backlash Signals Possible Shift in Washington and on Wall Street

After the shooting in Midtown Manhattan, there has been an outpouring of negative public sentiment directed at private insurers.
After the shooting in Midtown Manhattan, there has been an outpouring of negative public sentiment directed at private insurers. – Yuki Iwamura/Bloomberg

Health insurers were looking forward to an improved political environment in the Trump administration. Things might not turn out to be so simple.

After four years of stringent oversight under President Biden, a Donald Trump victory has been expected to usher in regulatory relief, particularly for the Medicare Advantage sector. Trump’s pick to lead the Centers for Medicare and Medicaid Services, the TV personality Mehmet Oz, has voiced strong support for private insurers. Meanwhile, Robert F. Kennedy Jr., Trump’s pick for health and human services secretary, is a tough critic of the pharmaceutical and food industries, with hardly any mention of insurance companies.

But in the wake of the fatal shooting of a UnitedHealth Group executive, there has been an outpouring of negative public sentiment toward private insurers. “Remembering the day United Healthcare denied a one-night hospital stay for my 12yo child as ‘medically unnecessary’ following ASD heart repair surgery,” wrote one user on X. Another shared this: “Today I’m thinking about the time United Healthcare suddenly decided to stop paying for my chemotherapy and didn’t bother telling me.” A Facebook post from the company expressing sorrow over the killing of Brian Thompson, chief executive of the insurance unit, prompted more than 70,000 laugh emojis. “Thoughts and prior authorizations,” went a typical comment.

Joking about the murder of a human being—a husband and father—is deeply insensitive. The claims made about UnitedHealthcare by individuals on X haven’t been independently verified. And it should be needless to say that no one should face threats or violence, no matter how contentious the debate over health policy might be.

Yet the negative feelings on display toward health insurers can’t be ignored, including by policymakers, the companies themselves and their shareholders. At the very least, they underscore the widespread anger over the perceived dysfunction of the American healthcare system, and expose it as even more deep-seated than how it previously might have been understood. In recent years, insurers have been accused of denying coverage to protect their profit margins, a criticism that the killer seemingly alluded to with the words “deny,” “defend” and “depose” scrawled with a permanent marker on bullet casings found outside the Midtown Hilton.

UnitedHealth Group’s stock has dropped sharply in recent days, a decline partly attributed to the company’s forecast, released the day before the fatal shooting. It projected higher-than-expected medical costs for the company in 2025.

Investors might also be concerned that there will be even greater scrutiny on certain insurer practices such as prior authorizations—a health plan’s requirement for a doctor to get approval before providing a service—which the Biden administration had already begun cracking down on. In such an environment, Republicans could support some of these measures, and insurance executives themselves could tread more carefully when it comes to denying medical claims.

From the election through Tuesday, the day before the killing, the shares of health insurers such as UnitedHealth, Humana and CVS Health beat the broader market, reflecting optimism about a more favorable regulatory environment, particularly for Medicare Advantage.

Analysts and investors will now be watching closely how the incoming Trump administration appears to be leaning. For now, most still expect traditional Republican priorities, such as trying to shift more patients into privately administered Medicare Advantage, to prevail.

Wall Street remains bullish on UnitedHealth. On Friday, Sarah James, an analyst at Cantor Fitzgerald, raised her price target for the company to $700. Other analysts appear to share a positive view, with 21 of 25 analysts on FactSet rating UnitedHealth shares as a “buy” or “overweight.”

But this stance could prove complacent. The full consequences of the shooting won’t be fully understood for some time. But the outpouring of negative sentiment toward insurers has at the very least made things more complicated for them, and for Republicans hoping to deregulate them.

Write to David Wainer at david.wainer@wsj.com

EMEA Tribune is not involved in this news article, it is taken from our partners and or from the News Agencies. Copyright and Credit go to the News Agencies, email news@emeatribune.com Follow our WhatsApp verified Channel210520-twitter-verified-cs-70cdee.jpg (1500×750)

Support Independent Journalism with a donation (Paypal, BTC, USDT, ETH)
WhatsApp channel DJ Kamal Mustafa